Company Description
Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company focused on developing delivering treatments for patients with a range of genetic and vascular disorders. CUV’s lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).
Clinuvel Pharmaceuticals Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.clinuvel.com.
This a small cap company with market cap of 1250 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is greater than both sector and market. while Company PB is greater than both sector and market. On the other hand,
| Earnings | PE | PB | PE growth | |
|---|---|---|---|---|
| Company | 0.91 | 76.7 | 17 | 0 |
| Market | 0.85 | 22.3 | 1.99 | 0.84 |
| Sector | 1.7 | 39.6 | 5.78 | 0.26 |
Dividend Growth Chart
The following chart shows you how cuv dividend grows in the recent years.Clinuvel Pharmaceuticals Limited has dividend yield of 0.10%